Professional Documents
Culture Documents
valued at $14.3 billion in 2012 and is projected to witness HIV therapeutics market
growth of 1.9% during the 20122019 forecast period to reach $16.3 billion.
Scope
The report analyzes treatment usage patterns, drug types available and pipeline and
market forecasts across indications for HIV. The Global HIV Therapeutics Market
Analysis report covers and includes A brief introduction to HIV, including the symptoms, pathogenesis, risk factors and
diagnosis
In-depth analysis of major glucose-lowering drugs for HIV, including analyses of their
safety, efficacy, treatment patterns, strengths/weaknesses and
overall commercial prospects. Includes a heat map comparing major drugs in terms of
safety, efficacy and dosing parameters.
Comprehensive review of the pipeline for HIV therapies, including individual analysis
of a number of late-stage pipeline drugs that are likely to enter the market in the
forecast period. The pipeline is analyzed on the basis of phase distribution, molecule
types and molecular targets.
Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type,
trial size, trial duration and program failure rate analyses for each molecule type and
mechanism of action
Multi-scenario forecast data for the market up to 2019, taking into account how it will
be affected by the introduction of new drugs, the expiry of key patents on current
drugs, and changes in disease epidemiology across key developed markets including
the US, Japan, Germany, the UK, France, Italy, Spain and Canada
Discussion of the drivers and barriers for market growth
Reasons to buy
The report will enhance your decision-making capability. It will allow you to JSB Market Research Pvt. Ltd.
Align your product portfolio to the markets with high growth potential.
Develop market-entry and market expansion strategies by identifying the potential
region and HIV/AIDS therapeutics market segments poised for strong growth.
Create a more tailored country strategy through the understanding of key drivers and
barriers of the global HIV/AIDS therapeutics market.
Develop key strategic initiatives by understanding the key focus areas and top selling
products of leading companies.
Accelerate and strengthen your market position by identifying key companies for
mergers, acquisitions and strategic partnerships.
2.6 Symptoms
2.7 Diagnosis
2.7.1 HIV Antibody Assay
2.7.2 Rapid HIV Antibody Test
2.7.3 Western Blot
2.7.4 HIV p24 Antigen Test
2.7.5 Antigen-Antibody Immunoassay
2.7.6 Polymerase Chain Reaction Test
2.7.7 HIV Home-Testing Kit
2.8 Disease Staging
2.8.1 WHO Clinical Staging
2.8.2 Centers for Disease Control and Prevention Classification System
2.8.3 Immunological Classification
2.9 Co-morbidities and Complications
2.10 Epidemiology
2.11 Treatment Options
2.11.1 Nucleoside/Nucleotide Reverse Transcriptase Inhibitor
2.11.2 Non-Nucleoside Reverse Transcriptase Inhibitor
2.11.3 Entry Inhibitor
2.11.4 Integrase Inhibitor
2.11.5 HIV-1 Protease Inhibitor
2.11.6 Pharmacokinetic Enhancer
2.12 Treatment Algorithm
3 Marketed Products
3.1 Therapeutic Landscape
3.1.1 Multi-class Combinations
3.1.2 Nucleotide Reverse Transcriptase Inhibitors
3.1.3 Non-Nucleoside Reverse Transcriptase Inhibitor
3.1.4 HIV Protease Inhibitor
3.1.5 Integrase Inhibitor
3.1.6 Entry Inhibitor
3.2 Comparative Efficacy and Safety
3.2.1 Multi-class Combination
3.2.2 Nucleotide Reverse Transcriptase Inhibitor
3.2.3 Non-Nucleotide Reverse Transcriptase Inhibitor
JSB Market Research Pvt. Ltd.
List Of Figures
Figure 1: HIV Therapeutics Market, Treatment Algorithm for HIV-infected Adults and
Adolescents under World Health Organization Guidelines, 2013
JSB Market Research Pvt. Ltd.
Figure 2: HIV Therapeutics Market, Treatment Algorithm for Infants and Children with
HIV under World Health Organization Guidelines, 2013
Figure 3: HIV Therapeutics Market, Global, Annual Sales of Key Marketed Products
($bn), 2013
Figure 4: HIV Therapeutics Market, Global, Annual Sales of Atripla ($bn), 20062013
Figure 5: HIV Therapeutics Market, Global, Annual Sales of Complera ($m), 20112013
Figure 6: HIV Therapeutics Market, Global, Annual Sales of Truvada ($bn), 20042013
Figure 7: HIV Therapeutics Market, Global, Annual Sales of Epzicom ($m), 20042013
Figure 8: HIV Therapeutics Market, Global, Annual Sales of Viread ($m), 20012013
Figure 9: HIV Therapeutics Market, Global, Annual Sales of Combivir ($m), 20002013
Figure 10: HIV Therapeutics Market, Global, Annual Sales of Trizivir ($m), 20002013
Figure 11: HIV Therapeutics Market, Global, Annual Sales of Epivir ($m), 19962013
Figure 12: HIV Therapeutics Market, Global, Annual Sales of Sustiva ($m), 20012013
Figure 13: HIV Therapeutics Market, Global, Annual Sales of Intelence ($m), 20102013
Figure 14: HIV Therapeutics Market, Global, Annual Sales of Reyataz ($m), 20032013
Figure 15: HIV Therapeutics Market, Global, Annual Sales of Prezista ($m), 20062013
Figure 16: HIV Therapeutics Market, Global, Annual Sales of Kaletra ($bn), 20092012
Figure 17: HIV Therapeutics Market, Global, Annual Sales of Norvir ($m), 20102012
Figure 18: HIV Therapeutics Market, Global, Annual Sales of Isentress ($m), 20072013
Figure 19: HIV Therapeutics Market, Global, Annual Sales of Selzentry ($m), 20102013
Figure 20: HIV Therapeutics Market, Global, Heat Map of Marketed Products, 2013
Figure 21: HIV Therapeutics Market, Global, Overall Pipeline, 2014
Figure 22: HIV Therapeutics Market, Global, Breakdown of Biologics and Vaccine, 2014
Figure 23: HIV Therapeutics Market, Global, Mechanism of Action in the Pipeline, 2014
Figure 24: HIV Therapeutics Market, Global, Clinical Trial Failure Rate by Molecule
Type, 20062013
Figure 25: HIV Therapeutics Market, Global, Clinical Trial Failure Rate by Mechanism of
Action, 20062013
Figure 26: HIV Therapeutics Market, Global, Clinical Trial Failure Reasons, 20062013
Figure 27: HIV Therapeutics Market, Global, Mean Recruitment Size of Clinical Trial by
Molecule Type (Participants), 20062013
Figure 28: HIV Therapeutics Market, Global, Mean Recruitment Size of Clinical Trial by
Mechanism of Action (Participants), 20062013
Figure 29: HIV Therapeutics Market, Global, Mean Duration of Clinical Trial by Molecule
Type (Months), 20062013*
Figure 30: HIV Therapeutics Market, Global, Mean Duration of clinical Trial by
Mechanism of Action (Months), 20062013
JSB Market Research Pvt. Ltd.
Figure 31: HIV Therapeutics Market, Global, Failure Rate, Duration and Recruitment
Size by Mechanism of Action, 20062013
Figure 32: HIV Therapeutics Market, Global, Sales Forecast for 572-Trii ($bn), 2014
2019
Figure 33: HIV Therapeutics Market, Global, Sales Forecast for Atazanavir Sulfate +
Cobicistat ($m), 20142019
Figure 34: HIV Therapeutics Market, Global, Sales Forecast for Elvitegravir + Cobicistat
+ Emtricitabine + Tenofovir Alafenamide ($m), 20152019
Figure 35: HIV Therapeutics Market, Global, Sales Forecast for Apricitabine ($m), 2016
2019
Figure 36: HIV Therapeutics Market, Global, Sales Forecast for Censavudine ($m),
20162019
Figure 37: HIV Therapeutics Market, Global, Sales Forecast for Elvucitabine ($m),
20162019
Figure 38: HIV Therapeutics Market, Global, Sales Forecast for Cenicriviroc ($m), 2016
2019
Figure 39: HIV Therapeutics Market, Global, Heat Map of Pipeline Products, 2013
Figure 40: HIV Therapeutics Market, Global, Competitor Matrix, 2013
Figure 41: HIV Therapeutics Market, Global, Treatment Patterns and Market Size,
20122019
Figure 42: HIV Therapeutics Market, North America, Treatment Patterns, 20122019
Figure 43: HIV Therapeutics Market, North America, Annual Cost of Therapy ($), 2012
2019
Figure 44: HIV Therapeutics Market, North America, Market Size, 20122019
Figure 45: HIV Therapeutics Market, Top Five European Countries, Treatment Patterns
(000), 20122019
Figure 46: HIV Therapeutics Market, Top Five European Countries, Annual Cost of
Therapy ($), 20122019
Figure 47: HIV Therapeutics Market, Top Five European Countries, Market Size ($m),
20122019
Figure 48: HIV Therapeutics Market, Japan, Treatment Patterns and Annual Cost of
Therapy, 20122019
Figure 49: HIV Therapeutics Market, Japan, Market Size ($m), 20122019
Figure 50: HIV Therapeutics Market, Global, Co-development Deals, 20062014*
Figure 51: HIV Therapeutics Market, Global, Co-development Deals, 20062014
Figure 52: HIV Therapeutics Market, Global, Licensing Deals, 20062014*
Figure 53: HIV Therapeutics Market, Global, Licensing Deals, 20062014
JSB Market Research Pvt. Ltd.
Figure 54: HIV Therapeutics Market, Global, Licensing Deals by Mechanism of Action,
20062014
Figure 55: Authors Market Forecasting Model
Product Price :
License Type
Price
$ 4995
Site Licence
$ 9990
$ 14985
Related reports:
Electrophoresis Market by Product (1D & 2D Gel Electrophoresis, Agarose &
Polyacrylamide Gel, Capillary Electrophoresis, Isoelectric Focusing,
JSB Market Research Pvt. Ltd.
Forecast to 2019
Europe Spine Surgery Devices Market by Product (Spinal Fusion & Fixation
Devices, Spine Biologics, Non-Fusion Implants, Spine Bone Stimulators), by
End-User (Orthopedic Clinics & Spine Centers, Hospitals), by Geography
Analysis & Forecast to 2019
Healthcare and Medical Market Research
You can order this report by calling on +91 - 998 7295 242 or mail us your
contact details at contact@jsbmarketresearch.com
About JSB Market Research:JSB market research is amongst the best online market research companies providing
the most significant online database of various industry research reports and services.
This online portal contains high-quality market research reports with well-researched
content on a wide range of industries. We specialize in providing the best market
research reports for various industries.
http://www.jsbmarketresearch.com/c-medical/r-hiv-therapeutics-in-majordeveloped-markets-to-2019-limited-pipeline-efficacy-improvement-151137